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C′-CEO SLOWS POST-TRAUMATIC OA PROGRESSION AND RELIEVES
OA-RELATED PAIN
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J.A. Hardin y, R.J. Majeska z, D.C. Spray y, M.B. Goldring x, N.J. Cobelli y,
H.B. Sun y. yAlbert Einstein Coll. of Med., Bronx, NY, USA; z The City Coll. of
New York, New York, NY, USA; xHosp. for Special Surgery, New York, NY,
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Purpose: There is currently no cure for osteoarthritis (OA) and no
therapy that will slow or arrest progression of this disease. Our previous
studies identiﬁed a transcriptional regulator, Cbp/p300 Interacting
Transactivator 2 (CITED2) that mediates chondroprotection, at least in
part by suppressing expression of proteases including the matrix met-
alloproteinase MMP-13 and the aggrecanase ADAMTS5. Using a tar-
geted screening approach, we found four nutraceuticals (carvacrol [C0],
curcumin [C], green tea polyphenol Epigallocatechin gallate [E], and
oligomeric proanthocyanidins [O]), that individually increased the
expression of CITED2 and reduced the expression of MMPs and
ADAMTS in human chondrocytes in vitro. The objective of the present
study was to determine the efﬁcacy of the combination of these
nutraceuticals (C0-CEO) in chondroprotection in vitro and in vivo using
an OA disease model that includes symptom modiﬁcation.
Methods:Human chondrocyte culture: Human chondrocytic cells (C28/
I2) were treated with Carvacrol (C0, 1mM), Curcumin (C, 1mM), EGCG (E,
100mM), OPC (O, 50mg/ml), or C0-CEO (combination of all 4 compounds)
for 24 hours in the presence of IL-1b (10ng/ml). Relative mRNA levels of
MMPs 1, 3,13, ADAMTS5, TNF-a, and CITED2were analyzed by real-time
PCR. n¼6. * p<0.05 using one-way ANOVA and Tukey post-hoc test.
Mice (C57BL/6, male, 6 months-old, n¼8/group) were subjected to
destabilization of the medial meniscus (DMM) and treated daily (7
days/week) with Carvacrol (C0: 50mg/kg), Curcumin (C: 50mg/kg),
Epigallocatechin gallate (E: 5mg/kg), oligomeric proanthocyanidins (O:
50mg/kg), C0-CEO (combination of all 4 compounds), or vehicle for 8
weeks via oral gavage with naïve mice as an additional control. OA
assessments: Arthritic pain was assessed at 8 weeks following DMM
surgery using assays of von Frey (mechanical allodynia) and open ﬁeld.
OA severity was evaluated by OARSI scoring of Safranin O-stained tissue
sections from decalciﬁed, formalin-ﬁxed hind limbs. Immunohis-
tochemistry was used to detect cleaved aggrecan and type II collagen in
the cartilage extracellular matrix and MMP-13, ADAMTS5, and CITED2
positive chondrocytes.
Results: In vitro, the combination treatment, C0-CEO, was more potent
than any individual compound in reducing mRNA levels of MMP-3,
MMP-13, ADAMTS-5 and TNF-a and increasing CITED2 mRNA (Fig 1),
indicating a synergistic chondroprotective effect of the 4 compounds as
a potential OA therapeutic. In vivo, while each individual compound
reduced OA disease progression, C0-CEO-treated mice exhibited the
lowest OA score and best preservation of the articular cartilage from
thinning and surface damage compared to that observed in vehicle-
treated DMM mice (Fig 2A). C0-CEO also protected against type II col-
lagen and aggrecan cleavage, and reduced MMP-13 and ADAMTS5
immunostaining (Fig 2B). Furthermore, C0-CEO treatment restored the
percentage of CITED2-positive chondrocytes from 28±3% (vehicle) to
55±6% (C0-CEO; C0-CEO vs. vehicle p<0.05), similar to that in naïve mice
(51±3%, Fig 2C). With regards to pain, C0-CEO-treated DMM mice, like
naïve controls, required a higher force to elicit pawwithdrawal (p<0.05,
Fig 3A), traveled a longer distance (p<0.05, Fig 3B), and increased
rearing (p<0.05, Fig 3C), indicating that C0-CEO exerted a signiﬁcant
relief of pain symptoms related to OA.
Conclusions: A novel nutraceutical formulation, C0-CEO, increases lev-
els of CITED2 and is effective in slowing OA progression and in relieving
OA-related pain in an OA animal model. These ﬁndings provide a
rational basis for advancing this product as an intervention for OA
prevention and treatment.545
THE EFFECTS OF TREATMENT ON DISEASE SYMPTOMS AND
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Purpose: The impact of meniscal extrusion on response to treatment
could be a clinically relevant concern in the context of personalized
management of osteoarthritis (OA).
The aim of this study was to evaluate the role of meniscal extrusion on
the effects of conventional OA pharmacological treatment and those of
glucosamine and chondroitin sulfate (Glu/CS) on knee structural
changes, using data from the progression cohort of the OA Initiative
(OAI).
The OAI allows the study of potential disease-modifying OA drug
(DMOAD) effects in patients over time following the evolution of OA
structural changes and the associated risk factors.
Methods: Participants (n¼600) were selected from the OAI progression
cohort (n¼1,390) if they had 24 consecutive months follow-up with
complete radiographic and magnetic resonance imaging (MRI) data for
the most symptomatic knee based on the highest WOMAC pain score at
the onset of the study (Time [T] 0).
Those participants were stratiﬁed into two main groups based on
whether (þ) or not (-) standard pharmacological treatment for OA
(analgesics and non-steroidal anti-inﬂammatory drugs [NSAIDs]) was
taken for disease symptoms over a continuous period of 24 months
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groups based on whether or not subjects had meniscal extrusion at
baseline and further on whether or not they received a combination of
Glu and CS.
The main outcomes were knee structural changes including the loss of
joint space width (JSW) and cartilage volume loss measured by quan-
titative MRI (qMRI).
Results: Participants reported taking (þ) (n¼300) or not taking (-)
(n¼300) OA treatment (analgesics/NSAIDs) over 24 months, with or
without Glu/CS. The participants with meniscal extrusion had more
knee OA structural damage at baseline and more knee OA progression
as assessed by both X-rays and qMRI. Patients in both - andþanalgesics/
NSAIDs groups with meniscal extrusion had signiﬁcantly greater carti-
lage volume loss in the medial compartment compared to those with-
out meniscal extrusion.
No signiﬁcant effect on JSW loss was found at T24 between - and
þanalgesics/NSAIDs groups, regardless of the presence or absence of
meniscal extrusion and of the consumption or not of Glu/CS, whereas
signiﬁcant differences emerged for cartilage volume loss when exam-
ined by qMRI.
In the -analgesics/NSAIDs group (mild disease) with meniscal extrusion
(more progressive disease) participants taking Glu/CS had less cartilage
volume loss in the plateau (p¼0.01). Multivariate analyses further
conﬁrmed in the -analgesics/NSAIDs group, that those with meniscal
extrusionwho took Glu/CS had signiﬁcantly less cartilage volume loss in
the medial plateau (p¼0.009).
In the þanalgesics/NSAIDs group, at T24, participants without meniscal
extrusion (moderate disease) taking Glu/CS had less cartilage volume
loss in the global (p0.002, univariate and multivariate analyses) and
medial and lateral plateaus (p¼0.034, p¼0.013, respectively, multi-
variate analysis). However, in participants with meniscal extrusion
(severe disease), although those taking Glu/CS had signiﬁcantly less
cartilage volume loss in themedial condyle at T24 in univariate analysis,
this ﬁnding was not conﬁrmed in multivariate analysis.
Conclusions: The presence of meniscal extrusion is an important factor
that can inﬂuence the drug effect on cartilage volume. X-rays were
found to be much less sensitive than MRI at documenting the protective
effect of treatment on structural changes. Indeed, with qMRI, the
-analgesics/NSAIDs group subjects with meniscal extrusion (mild but
progressive disease) demonstrated that Glu/CS prevented cartilage
volume loss in the medial plateau with a trend in the medial tibiofe-
moral compartment (Figure 1). In the þanalgesics/NSAIDs group, the
Glu/CS prevented cartilage volume loss in the global plateau in the
subjects without meniscal extrusion (moderate disease) (Figure 2). The
non-effect of Glu/CS on patients without meniscal extrusion not taking
analgesics/NSAIDs, representing very mild disease, probably reﬂects
that the cartilage volume loss was small and unlikely to provide an
accurate estimate. Moreover, in subjects with meniscal extrusion who
took analgesics/NSAIDs (severe disease), the non-effect observed likely
reﬂects irreversible cartilage damage.
This study conﬁrms that combined administration of Glu/CS has a sig-
niﬁcant beneﬁcial effect at delaying knee OA cartilage volume loss in
subjects with mild to moderate disease severity.546
CARNOSIC ACID INDUCES HEME OXYGENASE-1 AND SUPPRESSES
PROTEOGLYCAN RELEASE
H. Ishitobi, C. Shibata, S. Yamasaki, S. Miyaki, K. Matsubara. Hiroshima
Univ., Hiroshima, Japan
Purpose: Osteoarthritis (OA) is associated with age-related loss of
cartilage homeostatic balance. Antioxidant and autophagy are an
important mechanism to maintain cellular homeostasis under various
stresses and its activity decreases with aging and OA development.
Recently, we reported that the deﬁciency of Bach1, transcriptional
repressor, reduces the severity of OA-like changes through upregulated
heme oxygenase-1 (HO-1), which is cytoprotective through its anti-
oxidant effects. Thus, enhancement of HO-1 may prevent age-related
diseases such as OA. Several foods are also effective as prevention of
oxidant stress. Epidemiology data suggest that high intake of fruit and
vegetables protect against the onset and/or progression of OA. Carnosic
acid (CA) is a natural compound in rosemary and common sage, and it
has the cytoprotective effects via the potential of antioxidant and anti-
inﬂammation. The object of this study was to examine whether CA
would be effective for OA prevention.
Methods: Human synovial ﬁbroblasts and chondrocytes were obtained
from Dr. Martin K Lotz (The Scripps Research Institute, USA). Normal
human knee synovial ﬁbroblasts and chondrocytes were isolated from
autopsy donors as leftover de-identiﬁed material and with no inter-
actions with subjects, and therefore with no informed consent
required. The human chondrocyte and synovial ﬁbroblast was plated at
5 x 104 per well into 24 well plates. These cells were treated with 1, 5,
10, 25, 50 mM CA for 24 h. The expression of HO-1 and autophagy
marker LC3 was analysed using immunoblotting. We examined
whether the expression of OA-related genes COL2a1, AGGRECAN, IL-1b,
IL-6, MMP-3, -13 and ADAMTS-5 can be regulated by CA, when
synovial ﬁbroblasts and chondrocytes were stimulated with IL-1b (1
ng/ml) for 24 h. To examine whether CA effects on prevention of
cartilage degradation, we performed Glycosaminoglycan (GAG) release
assay using mouse cartilage explants. Femoral heads were harvested
from 4-week-old C57BL/6 mice and incubated at 37 C for 72 h in 48-
well plates. The cartilage samples were cultured for 72h in 500 ml of
serum-free DMEM containing CA 10 or 50 mM with or without IL-1b.
For studies on CA drinking, we evaluated the levels of HO-1 in
response to CA drinking in the knee joints by immunohistochemistry.
Furthermore, the senescence-accelerated mouse (SAMP8) was used as
a primary OA, and 3-months old male SAMP8 mice were bred with
free access to drinking water including CA (50 mM) for 10-months. The
knee joints were stained with Safranin O and grade by the OA scoring
systems.
Results: The expression of HO-1 was upregulated in human synovial
ﬁbroblasts and chondrocytes treated with CA in a dose-dependent
manner. LC3 was not induced by CA. CA had no effect on the expression
of Col2a1 and AGGRECAN in chondrocytes. Although the expression of
IL-1b, IL-6, MMP-3, -13 and ADAMTS-5 was upregulated by IL-1b in the
human synovial ﬁbroblasts and chondrocytes, the expression of IL-1b,
MMP-13 was signiﬁcantly downregulated by CA. In GAG release assay
using cartilage explants, CA decreased proteoglycan release. Finally, to
determine whether CA would be effective in OA model mice as a sup-
plement, we performed the histologic evaluation of knee joints in
SAMP8. Although the severity of cartilage destruction was trend
towards differences in the CA drinking group compared with control
group, none of the differences were statistically signiﬁcant. HO-1 was
not markedly induced by orally administered CA in joint tissues
including cartilage, however, it suppressed age-related hepatic
steatosis.
Conclusions: This study showed that CA induced HO-1 in synovial
ﬁbroblasts and chondrocyte and suppressed proteoglycan release from
cartilage via downregulation of IL-1b, MMP-13. However, orally
administered CA could not prevent spontaneous age-related OA. These
ﬁndings suggest that CA is an effective HO-1 inducer and have a
potential to be supplement for OA prevention.
